The france diabetes devices market size is projected to expand from USD 1.39 billion in 2025 and USD 1.47 billion in 2026 to USD 2.02 billion by 2031, registering a CAGR of 6.56% between 2026 to 2031. This report is Segmented by Device Type (Glucose Monitoring Devices, Insulin Delivery Devices, and Other Diabetes-Care Devices), Diabetes Type (Type 1 Diabetes, Type 2 Diabetes, and Gestational & Others), End User (Hospitals & Clinics, Specialty Clinics, Home-Care Settings, and More). The Market Provides the Value (in USD) for the Above-Mentioned Segments.
Second-generation pumps are split between tethered (MiniMed 780G, Tandem Control-IQ) and tubeless (Omnipod 5, Kaleido) designs. Recall-driven sensor shortages can temporarily re-inflate SMBG demand, but a structural shift favors sensors and smart pumps.
France Diabetes Devices Market Trends and Insights
Mainstream Reimbursement Expansion for CGM Sensors
France approved full reimbursement of Dexcom ONE for 100,000 Type 2 patients on basal insulin in June 2024, opening the first European CGM pathway for non-intensive users. Health-economic studies place the incremental cost-effectiveness ratio within national thresholds, reinforcing payer support. As volumes rise, price-volume clauses lower per-sensor reimbursement, limiting manufacturer margins. Integrated sensor-transmitter ecosystems help offset this pressure by locking users into subscription refill models. The 2025 revision of the EU Medical Device Regulation (MDR) embeds post-market surveillance requirements, so real-world CGM outcomes feed directly into reimbursement renewal.Rapid Uptake of Tubeless and Patch Insulin Pumps
Insulet introduced Omnipod 5 in June 2024, meeting the demand for a discreet, adhesive-based therapy among lifestyle-conscious Type 1 patients. Real-world surveys of 14,765 users show satisfaction driven by convenience rather than superior glycemic metrics. Grenoble-based Diabeloop secured EUR 15 million in 2024 to speed DBLG1 adoption and prepare the smartphone-native DBLG2, which gained FDA clearance by January 2026. The MiniMed 780G spin-off announced by Medtronic in June 2025 underscores escalating competition as agile software innovators shorten upgrade cycles. Future pump growth depends on algorithmic personalization, patch-format miniaturization, and bundle offers that pair hardware, sensor, and support.Price-Volume Clauses Squeezing Margins
French price tariffs fall once sales thresholds are crossed, curbing profit despite rising CGM penetration. Dexcom ONE reimbursement illustrates this pinch: higher volumes trigger steeper rebates. Manufacturers introduce premium variants with longer wear or predictive alerts to escape existing caps. The 2025 FreeStyle Libre 3 recall shows how speed-to-market gambits carry quality risk that can magnify financial strain.Other drivers and restraints analyzed in the detailed report include:
- Smartphone-Integrated SMBG Ecosystems
- Rapid GLP-1 Adoption Shifting Device Mix
- Sensor Cybersecurity and GDPR Compliance Burden
Segment Analysis
The French diabetes devices market size remained at 57.23% of the French diabetes devices market share that year. Sensors remain volume leaders, yet their growth trails pumps, as margin pressure from price-volume clauses tempers revenue gains. AID-capable patch pumps underpin the 7.87% CAGR in insulin delivery, helped by Omnipod 5 and DBLG1 rollouts. Self-monitoring glucometers continue to lose ground as CGM reimbursement widens and fingerstick avoidance intensifies.Second-generation pumps are split between tethered (MiniMed 780G, Tandem Control-IQ) and tubeless (Omnipod 5, Kaleido) designs. Recall-driven sensor shortages can temporarily re-inflate SMBG demand, but a structural shift favors sensors and smart pumps.
Complete Report Scope:
- By Device Category
- Glucose Monitoring Devices
- Self-Monitoring Blood Glucose (SMBG) Devices
- Glucometers
- Test Strips
- Lancets
- Continuous Glucose Monitoring (CGM) Devices
- Sensors
- Durables (Receivers & Transmitters)
- Self-Monitoring Blood Glucose (SMBG) Devices
- Insulin Delivery Devices
- Insulin Pens
- Insulin Pumps
- Insulin Syringes
- Jet Injectors
- Other Diabetes-Care Devices
- Glucose Monitoring Devices
- By Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational & Others
- By End User
- Hospitals
- Specialty Clinics
- Home Care Settings
- Other End Users
List of Companies Covered in this Report:
- Abbott Laboratories
- Ascensia
- B. Braun
- Beckton Dickinson
- Dexcom
- Eli Lilly and Company
- Gan & Lee Pharm
- Insulet
- Lepu Medical
- Lifescan
- Medtronic
- MicroPort
- MicroTech Medical Co.
- Novo Nordisk
- Roche
- Sanofi
- Senseonics Holdings
- Sinocare
- Tandem Diabetes Care
- Ypsomed
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value & Volume)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Diabetes Care
- Ascensia Diabetes Care
- B. Braun Melsungen AG
- Becton Dickinson and Company
- Dexcom Inc.
- Eli Lilly and Company
- Gan & Lee Pharm
- Insulet Corporation
- Lepu Medical Technology
- LifeScan
- Medtronic
- MicroPort Scientific
- MicroTech Medical Co.
- Novo Nordisk A/S
- Roche Diabetes Care
- Sanofi S.A.
- Senseonics Holdings
- Sinocare Inc.
- Tandem Diabetes Care
- Ypsomed AG
